Comparative Cost-Effectiveness Analysis of Avelumab plus Axitinib Versus Pembrolizumab plus Axitinib, Ipilimumab plus Nivolumab, and Sunitnib for Advanced Renal Cell Carcinoma in the U.k. Perspective.

AuthID
 P-016-70S
8
Author(s)
De Mello, RA
·
Ayoub, E
·
De Almeida Zia, VA
·
Savio, A
·
Pozza, DH
·
Tadokoro, H
·
Teich, N
Document Type
Article
Year published
2020
Published
in Journal of Clinical Oncology, ISSN: 0732-183X
Volume: 38, Issue: 6_suppl, Pages: 689-689
Indexing
Crossref®2
Google Scholar®
Publication Identifiers
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service